Evolution to a chronic disease niche correlates with increased sensitivity to Tryptophan availability for the obligate intracellular bacterium Chlamydia pneumoniae

Journal of Bacteriology

Volumn 196, Issue 11, 2014, Pages 1915-1924

  Huston, Wilhelmina M ^a   Barker, Christopher J ^a   Chacko, Anu ^a   Timms, Peter ^b  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b UNIVERSITY OF THE SUNSHINE COAST   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; INDOLEAMINE 2,3 DIOXYGENASE; TRYPTOPHAN;

ALZHEIMER DISEASE; ASTHMA; ATHEROSCLEROSIS; BACTERIAL STRAIN; CHLAMYDOPHILA PNEUMONIAE; CHRONIC DISEASE; CYTOLOGY; EVOLUTION; GENOME; HOST CELL; HUMAN; IMMUNE EVASION; INTRACELLULAR BACTERIUM; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; SHORT SURVEY; TARGET CELL;

ANIMALS; CHLAMYDOPHILA PNEUMONIAE; CHRONIC DISEASE; HUMANS; SPECIES SPECIFICITY; TRYPTOPHAN;

EID: 84899742950     PISSN: 00219193     EISSN: 10985530     Source Type: Journal    
DOI: 10.1128/JB.01476-14     Document Type: Short Survey

References (130)

1. Abdelrahman YM, Belland RJ. 2005. The chlamydial developmental cycle. FEMS Microbiol. Rev. 29:949-959. http://dx.doi.org/10.1016/j.femsre.2005.03.002.
2. Omsland A, Sager J, Nair V, Sturdevant DE, Hackstadt T. 2012. Developmental stage-specific metabolic and transcriptional activity of Chlamydia trachomatis in an axenic medium. Proc. Natl. Acad. Sci. U. S. A. 109:19781-19785. http://dx.doi.org/10.1073/pnas.1212831109.
3. Coombes BK, Mahony JB. 2002. Identification of MEK- and phosphoinositide 3-kinase-dependent signalling as essential events during Chlamydia pneumoniae invasion of HEp2 cells. Cell. Microbiol. 4:447-460. http://dx.doi.org/10.1046/j.1462-5822.2002.00203.x.
4. Lane BJ, Mutchler C, Al Khodor S, Grieshaber SS, Carabeo RA. 2008. Chlamydial entry involves TARP binding of guanine nucleotide exchange factors. PLoS Pathog. 4:e1000014. http://dx.doi.org/10.1371/journal.ppat.1000014.
5. Shimada K, Crother TR, Arditi M. 2012. Innate immune responses to Chlamydia pneumoniae infection: role of TLRs, NLRs, and the inflammasome. Microbes Infect. 14:1301-1307. http://dx.doi.org/10.1016/j.micinf.2012.08.004.
6. Beatty WL, Belanger TA, Desai AA, Morrison RP, Byrne GI. 1994. Tryptophan depletion as a mechanism of gamma interferon-mediated chlamydial persistence. Infect. Immun. 62:3705-3711.
7. Beatty WL, Byrne GI, Morrison RP. 1993. Morphologic and antigenic characterization of interferon g-mediated persistent Chlamydia trachomatis infection in vitro. Proc. Natl. Acad. Sci. U. S. A. 90:3998-4002. http://dx.doi.org/10.1073/pnas.90.9.3998.
8. Hanada H, Ikeda-Dantsuji Y, Naito M, Nagayama A. 2003. Infection of human fibroblast-like synovial cells with Chlamydia trachomatis results in persistent infection and interleukin-6 production. Microb. Pathog. 34:57-63. http://dx.doi.org/10.1016/S0882-4010(02)00189-4.
9. Nebe CT, Rother M, Brechtel I, Costina V, Neumaier M, Zentgraf H, Bocker U, Meyer TF, Szczepek AJ. 2005. Detection of Chlamydophila pneumoniae in the bone marrow of two patients with unexplained chronic anaemia. Eur. J. Haematol. 74:77-83. http://dx.doi.org/10.1111/j.1600-0609.2004.00353.x.
10. Rupp J, Droemann D, Goldmann T, Zabel P, Solbach W, Vollmer E, Branscheid D, DalhoffK, Maass M. 2004. Alveolar epithelial cells type II are major target cells for C. pneumoniae in chronic but not in acute respiratory infection. FEMS Immunol. Med. Microbiol. 41:197-203. http://dx.doi.org/10.1016/j.femsim.2004.03.004.
11. Sieper J, Braun J. 2002. Diagnosis and antibiotic treatment of reactive arthritis. Dtsch. Med. Wochenschr. 127:1893-1896. http://dx.doi.org/10.1055/s-2002-34068. (In German.)
12. Bauriedel G. 2000. Persistence of Chlamydia pneumoniae in coronary plaque tissue. Dtsch. Med. Wochenschr. 125:645. (In German.)
13. Hogan R, Mathews SA, Mukhopadhyay S, Summersgill JT, Timms P. 2004. Chlamydial persistence: beyond the biphasic paradigm. Infect. Immun. 72:1843-1855. http://dx.doi.org/10.1128/IAI.72.4.1843-1855.2004.
14. Lambden PR, Pickett MA, Clarke IN. 2006. The effect of penicillin on Chlamydia trachomatis DNA replication. Microbiology 152:2573-2578. http://dx.doi.org/10.1099/mic.0.29032-0.
15. Byrne GI, Ouellette SP, Wang Z, Rao JP, Lu L, Beatty WL, Hudson AP. 2001. Chlamydia pneumoniae expresses genes required for DNA replication but not cytokinesis during persistent infection of HEp-2 cells. Infect. Immun. 69:5423-5429. http://dx.doi.org/10.1128/IAI.69.9.5423-5429.2001.
16. Jones ML, Gaston JSH, Pearce JH. 2001. Induction of abnormal Chlamydia trachomatis by exposure to interferon-gamma or amino acid deprivation and comparative antigenic analysis. Microb. Pathog. 30:299-309. http://dx.doi.org/10.1006/mpat.2001.0433.
17. Wehrl W, Meyer TF, Jungblut PR, Müller EC, Szczepek AJ. 2004. Action and reaction: Chlamydophila pneumoniae proteome alteration in a persistent infection induced by iron deficiency. Proteomics 4:2969-2981. http://dx.doi.org/10.1002/pmic.200400917.
18. Akers JC, Tan M. 2006. Molecular mechanism of tryptophandependent transcriptional regulation in Chlamydia trachomatis. J. Bacteriol. 188:4236-4243. http://dx.doi.org/10.1128/JB.01660-05.
19. Bragina EY, Gomberg MA, Dmitriev GA. 2001. Electron microscopic evidence of persistent chlamydial infection following treatment. J. Eur. Acad. Dermatol. Venereol. 15:405-409. http://dx.doi.org/10.1046/j.1468-3083.2001.00342.x.
20. Mannonen L, Kamping E, Penttila T, Puolakkainen M. 2004. IFNgamma induced persistent Chlamydia pneumoniae infection in HL and Mono Mac 6 cells: characterization by real-time quantitative PCR and culture. Microb. Pathog. 36:41-50. http://dx.doi.org/10.1016/j.micpath.2003.09.001.
21. Mpiga P, Ravaoarinoro M. 2006. Effects of sustained antibiotic bactericidal treatment on Chlamydia trachomatis-infected epithelial-like cells (HeLa) and monocyte-like cells (THP-1 and U-937). Int. J. Antimicrob. Agents 27: 316-324. http://dx.doi.org/10.1016/j.ijantimicag.2005.11.010.
22. Mpiga P, Ravaoarinoro M. 2006. Chlamydia trachomatis persistence: an update. Microbiol. Res. 161:9-19. http://dx.doi.org/10.1016/j.micres.2005.04.004.
23. Moulder JW. 1993. Why is Chlamydia sensitive to penicillin in the absence of peptidoglycan? Infect. Agents Dis. 2:87-99.
24. Skilton RJ, Cutcliffen LT, Barlow D, Wang Y, Salim O, Lambden PR, Clarke IN. 2009. Penicillin induced persistence in Chlamydia trachomatis: high quality time lapse video analysis of the developmental cycle. PLoS One 4:e7723. http://dx.doi.org/10.1371/journal.pone.0007723.
25. Wyrick PB, Knight ST. 2004. Pre-exposure of infected human endometrial epithelial cells to penicillin in vitro renders Chlamydia trachomatis refractory to azithromycin. J. Antimicrob. Chemother. 54:79-85. http://dx.doi.org/10.1093/jac/dkh283.
26. Hoestgaard-Jensen K, Christiansen G, Honore B, Birkelund S. 2011. Influence of the Chlamydia pneumoniae AR39 bacteriophage varphiCPAR39 on chlamydial inclusion morphology. FEMS Immunol. Med. Microbiol. 62:148-156. http://dx.doi.org/10.1111/j.1574-695X.2011.00795.x.
27. Villegas E, Sorlozano A, Gutierrez J. 2010. Serological diagnosis of Chlamydia pneumoniae infection: limitations and perspectives. J. Med. Microbiol. 59:1267-1274. http://dx.doi.org/10.1099/jmm.0.020362-0.
28. Beaty CD, Grayston JT, Wang SP, Kuo CC, Reto CS, Martin TR. 1991. Chlamydia pneumoniae, strain TWAR, infection in patients with chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 144:1408-1410. http://dx.doi.org/10.1164/ajrccm/144.6.1408.
29. Bas S, Cunningham T, Kvien TK, Glennas A, Melby K, Vischer TL. 1996. Synovial fluid and serum antibodies against Chlamydia in different forms of arthritis: intra-articular IgA production in Chlamydia sexually acquired reactive arthritis. Br. J. Rheumatol. 35:548-552. http://dx.doi.org/10.1093/rheumatology/35.6.548.
30. Bauriedel G, Andrie R, Likungu JA, Welz A, Braun P, Welsch U, Luderitz B. 1999. Persistence of Chlamydia pneumoniae in coronary plaque tissue: a contribution to the infection and immune hypothesis concerning unstable angina. Dtsch. Med. Wochenschr. 124:1408-1413. (In German.) http://dx.doi.org/10.1055/s-2007-1024554.
31. Hahn D, Schure A, Patel K, Childs T, Drizik E, Webley W. 2012. Chlamydia pneumoniae-specific IgE is prevalent in asthma and is associated with disease severity. PLoS One 7:e35945. http://dx.doi.org/10.1371/journal.pone.0035945.
32. Borel N, Mukhopadhyay S, Kaiser C, Sullivan ED, Miller RD, Timms P, Summersgill JT, Ramirez JA, Pospischil A. 2006. Tissue MicroArray (TMA) analysis of normal and persistent Chlamydophila pneumoniae infection. BMC Infect. Dis. 6:152. http://dx.doi.org/10.1186/1471-2334-6-152.
33. Clancy R, Ren Z, Pang G, Fletcher P, D'Este C. 2006. Chronic Chlamydia pneumoniae infection may promote coronary artery disease in humans through enhancing secretion of interleukin-4. Clin. Exp. Immunol. 146:197-202. http://dx.doi.org/10.1111/j.1365-2249.2006.03185.x.
34. Clementsen P, Permin H, Norn S. 2002. Chlamydia pneumoniae infection and its role in asthma and chronic obstructive pulmonary disease. J. Investig. Allergol. Clin. Immunol. 12:73-79.
35. Cochrane M, Pospischil A, Walker P, Gibbs H, Timms P. 2003. Distribution of Chlamydia pneumoniae DNA in atherosclerotic carotid arteries: significance for sampling procedures. J. Clin. Microbiol. 41: 1454-1457. http://dx.doi.org/10.1128/JCM.41.4.1454-1457.2003.
36. Cochrane M, Pospischil A, Walker P, Gibbs H, Timms P. 2005. Discordant detection of Chlamydia pneumoniae in patients with carotid artery disease using polymerase chain reaction, immunofluorescence microscopy and serological methods. Pathology 37:69-75. http://dx.doi.org/10.1080/00313020400011284.
37. Cochrane M, Walker P, Gibbs H, Timms P. 2005. Multiple genotypes of Chlamydia pneumoniae identified in human carotid plaque. Microbiology 151:2285-2290. http://dx.doi.org/10.1099/mic.0.27781-0.
38. Saikku P, Wang SP, Kleemola M, Brander E, Rusanen E, Grayston JT. 1985. An epidemic of mild pneumonia due to an unusual strain of Chlamydia psittaci. J. Infect. Dis. 151:832-839. http://dx.doi.org/10.1093/infdis/151.5.832.
39. Heiskanen-Kosma T, Korppi M, Laurila A, Jokinen C, Kleemola M, Saikku P. 1999. Chlamydia pneumoniae is an important cause of community-acquired pneumonia in school-aged children: serological results of a prospective, population-based study. Scand. J. Infect. Dis. 31:255-259. http://dx.doi.org/10.1080/00365549950163536.
40. Kauppinen M, Saikku P. 1995. Pneumonia due to Chlamydia pneumoniae: prevalence, clinical features, diagnosis, and treatment. Clin. Infect. Dis. 21(Suppl 3):S244-S252. http://dx.doi.org/10.1093/clind/21.Supplement_3.S244.
41. Kauppinen MT, Herva E, Kujala P, Leinonen M, Saikku P, Syrjala H. 1995. The etiology of community-acquired pneumonia among hospitalized patients during a Chlamydia pneumoniae epidemic in Finland. J. Infect. Dis. 172:1330-1335. http://dx.doi.org/10.1093/infdis/172.5.1330.
42. Kauppinen MT, Saikku P, Kujala P, Herva E, Syrjala H. 1996. Clinical picture of community-acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia. Thorax 51:185-189. http://dx.doi.org/10.1136/thx.51.2.185.
43. Conklin L, Adjemian J, Loo J, Mandal S, Davis C, Parks S, Parsons T, McDonough B, Partida J, Thurman K, Diaz MH, Benitez A, Pondo T, Whitney CG, Winchell JM, Kendig N, Van Beneden C. 2013. Investigation of a Chlamydia pneumoniae outbreak in a Federal correctional facility in Texas. Clin. Infect. Dis. 57:639-647. http://dx.doi.org/10.1093/cid/cit357.
44. Al-Younes HM. 7 June 2013. High prevalence of Chlamydia pneumoniae infection in an asymptomatic Jordanian population. J. Microbiol. Immunol. Infect. http://dx.doi.org/10.1016/j.jmii.2013.04.004.
45. Haider M, Rizvi M, Malik A, Azam M, Rabbani MU. 2011. Acute and chronic Chlamydia pneumoniae infection and inflammatory markers in coronary artery disease patients. J. Infect. Dev. Ctries. 5:580-586. http://dx.doi.org/10.3855/jidc.1704.
46. Haubitz M, Brunkhorst R. 2001. C-reactive protein and chronic Chlamydia pneumoniae infection-long-term predictors for cardiovascular disease and survival in patients on peritoneal dialysis. Nephrol. Dial. Transplant. 16:809-815. http://dx.doi.org/10.1093/ndt/16.4.809.
47. Hoymans VY, Bosmans JM, Ieven M, Vrints CJ. 2002. Chlamydia pneumoniae and atherosclerosis. Acta Chir. Belg. 102:317-322.
48. Jha HC, Vardhan H, Gupta R, Varma R, Prasad J, Mittal A. 2007. Higher incidence of persistent chronic infection of Chlamydia pneumoniae among coronary artery disease patients in India is a cause of concern. BMC Infect. Dis. 7:48. http://dx.doi.org/10.1186/1471-2334-7-48.
49. Nagy A, Keszei M, Kis Z, Budai I, Tolgyesi G, Ungvari I, Falus A, Szalai C. 2007. Chlamydophila pneumoniae infection status is dependent on the subtypes of asthma and allergy. Allergy Asthma Proc. 28:58-63. http://dx.doi.org/10.2500/aap.2007.28.2957.
50. Balin BJ, Gerard HC, Arking EJ, Appelt DM, Branigan PJ, Abrams JT, Whittum-Hudson JA, Hudson AP. 1998. Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain. Med. Microbiol. Immunol. 187:23-42. http://dx.doi.org/10.1007/s004300050071.
51. Balin BJ, Little CS, Hammond CJ, Appelt DM, Whittum-Hudson JA, Gerard HC, Hudson AP. 2008. Chlamydophila pneumoniae and the etiology of late-onset Alzheimer's disease. J. Alzheimers Dis. 13:371-380.
52. Hannu T, Puolakkainen M, Leirisalo-Repo M. 1999. Chlamydia pneumoniae as a triggering infection in reactive arthritis. Rheumatology (Oxford) 38:411-414. http://dx.doi.org/10.1093/rheumatology/38.5.411.
53. Jackson LA, Wang SP, Nazar-Stewart V, Grayston JT, Vaughan TL. 2000. Association of Chlamydia pneumoniae immunoglobulin A seropositivity and risk of lung cancer. Cancer Epidemiol. Biomarkers Prev. 9:1263-1266.
54. Kocazeybek B. 2003. Chronic Chlamydophila pneumoniae infection in lung cancer, a risk factor: a case-control study. J. Med. Microbiol. 52: 721-726. http://dx.doi.org/10.1099/jmm.0.04845-0.
55. Koyi H, Brandén E, Gnarpe J, Gnarpe H, Steen B. 2001. An association between chronic infection with Chlamydia pneumoniae and lung cancer. A prospective 2-year study. APMIS 109:572-580.
56. Karnak D, Beder S. 2002. Treatment of Chlamydia pneumoniae infection and chronic obstructive pulmonary disease. Exp. Opin. Pharmacother. 3:1461-1470. http://dx.doi.org/10.1517/14656566.3.10.1461.
57. Karnak D, Beng-sun S, Beder S, Kayacan O. 2001. Chlamydia pneumoniae infection and acute exacerbation of chronic obstructive pulmonary disease (COPD). Respir. Med. 95:811-816. http://dx.doi.org/10.1053/rmed.2001.1159.
58. Rizzo A, Paolillo R, Iafusco D, Prisco F, Romano Carratelli C. 2012. Chlamydia pneumoniae infection in adolescents with type 1 diabetes mellitus. J. Med. Microbiol. 61:1584-1590. http://dx.doi.org/10.1099/jmm.0.048512-0.
59. Wang C, Gao D, Kaltenboeck B. 2009. Acute Chlamydia pneumoniae reinfection accelerates the development of insulin resistance and diabetes in obese C57BL/6 mice. J. Infect. Dis. 200:279-287. http://dx.doi.org/10.1086/599796.
60. Chen Z, Ji W, Wang Y, Yan Y, Zhu H, Shao X, Xu J. 2013. Epidemiology and associations with climatic conditions of Mycoplasma pneumoniae and Chlamydophila pneumoniae infections among Chinese children hospitalized with acute respiratory infections. Ital. J. Pediatr. 39:34. http://dx.doi.org/10.1186/1824-7288-39-34.
61. Berger L, Volp K, Mathews S, Speare R, Timms P. 1999. Chlamydia pneumoniae in a free-ranging giant barred frog (Mixophyes iteratus) from Australia. J. Clin. Microbiol. 37:2378-2380.
62. Hotzel H, Grossmann E, Mutschmann F, Sachse K. 2001. Genetic characterization of a Chlamydophila pneumoniae isolate from an African frog and comparison to currently accepted biovars. Syst. Appl. Microbiol. 24:63-66. http://dx.doi.org/10.1078/0723-2020-00016.
63. Bodetti TJ, Jacobson E, Wan C, Hafner L, Pospischil A, Rose K, Timms P. 2002. Molecular evidence to support the expansion of the hostrange of Chlamydophila pneumoniae to include reptiles as well as humans, horses, koalas and amphibians. Syst. Appl. Microbiol. 25:146-152. http://dx.doi.org/10.1078/0723-2020-00086.
64. Di Francesco A, Donati M, Mattioli L, Naldi M, Salvatore D, Poglayen G, Cevenini R, Baldelli R. 2006. Chlamydophila pneumoniae in horses: a seroepidemiological survey in Italy. New Microbiol. 29:303-305.
65. Pantchev A, Sting R, Bauerfeind R, Tyczka J, Sachse K. 2010. Detection of all Chlamydophila and Chlamydia spp. of veterinary interest using species-specific real-time PCR assays. Comp. Immunol. Microbiol. Infect. Dis. 33:473-484. http://dx.doi.org/10.1016/j.cimid.2009.08.002.
66. Theegarten D, Sachse K, Mentrup B, Fey K, Hotzel H, Anhenn O. 2008. Chlamydophila spp. infection in horses with recurrent airway obstruction: similarities to human chronic obstructive disease. Respir. Res. 9:14. http://dx.doi.org/10.1186/1465-9921-9-14.
67. Bodetti TJ, Viggers K, Warren K, Swan R, Conaghty S, Sims C, Timms P. 2003. Wide range of Chlamydiales types detected in native Australian mammals. Vet. Microbiol. 96:177-187. http://dx.doi.org/10.1016/S0378-1135(03)00211-6.
68. Feder A, Skipper J, Blair JR, Buchholz K, Mathew SJ, Schwarz M, Doucette JT, Alonso A, Collins KA, Neumeister A, Charney DS. 2011. Tryptophan depletion and emotional processing in healthy volunteers at high risk for depression. Biol. Psychiatry 69:804-807. http://dx.doi.org/10.1016/j.biopsych.2010.12.033.
69. Mace JL, Porter RJ, Dalrymple-Alford JC, Wesnes KA, Anderson TJ. 2011. The effects of acute tryptophan depletion on neuropsychological function, mood and movement in the healthy elderly. J. Psychopharmacol. 25:1337-1343. http://dx.doi.org/10.1177/0269881110389094.
70. Fallarino F, Grohmann U, Puccetti P. 2012. Indoleamine 2,3-dioxygenase: from catalyst to signaling function. Eur. J. Immunol. 42: 1932-1937. http://dx.doi.org/10.1002/eji.201242572.
71. Munn DH, Mellor AL. 2013. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol. 34:137-143. http://dx.doi.org/10.1016/j.it.2012.10.001.
72. Roan NR, Starnbach MN. 2008. Immune-mediated control of Chlamydia infection. Cell. Microbiol. 10:9-19. http://dx.doi.org/10.1111/j.1462-5822.2007.01069.x.
73. Farris CM, Morrison RP. 2011. Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model. Infect. Immun. 79: 986-996. http://dx.doi.org/10.1128/IAI.00881-10.
74. Rank RG, Whittum-Hudson JA. 2010. Protective immunity to chlamydial genital infection: evidence from animal studies. J. Infect. Dis. 201(Suppl 2):S168-S177. http://dx.doi.org/10.1086/652399.
75. Rothfuchs AG, Kreuger MR, Wigzell H, Rottenberg ME. 2004. Macrophages, CD4+or CD8+cells are each sufficient for protection against Chlamydia pneumoniae infection through their ability to secrete IFNgamma. J. Immunol. 172:2407-2415.
76. Rothfuchs AG, Trumstedt C, Wigzell H, Rottenberg ME. 2004. Intracellular bacterial infection-induced IFN-gamma is critically but not solely dependent on Toll-like receptor 4-myeloid differentiation factor 88-IFN-alpha beta-STAT1 signaling. J. Immunol. 172:6345-6353.
77. Batteiger BE, Tu W, Ofner S, Van Der Pol B, Stothard DR, Orr DP, Katz BP, Fortenberry JD. 2010. Repeated Chlamydia trachomatis genital infections in adolescent women. J. Infect. Dis. 201:42-51. http://dx.doi.org/10.1086/648734.
78. Halme S, Latvala J, Karttunen R, Palatsi I, Saikku P, Surcel HM. 2000. Cell-mediated immune response during primary Chlamydia pneumoniae infection. Infect. Immun. 68:7156-7158. http://dx.doi.org/10.1128/IAI.68.12.7156-7158.2000.
79. Bastidas RJ, Elwell CA, Engel JN, Valdivia RH. 2013. Chlamydial intracellular survival strategies. Cold Spring Harb. Perspect. Med. 3:a010256. http://dx.doi.org/10.1101/cshperspect.a010256.
80. Brunham RC, Rey-Ladino J. 2005. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nat. Rev. Immunol. 5:149-161. http://dx.doi.org/10.1038/nri1551.
81. Pawliczak R, Logun C, Madara P, Barb J, Suffredini AF, Munson PJ, Danner RL, Shelhamer JH. 2005. Influence of IFN-gamma on gene expression in normal human bronchial epithelial cells: modulation of IFN-gamma effects by dexamethasone. Physiol. Genomics 23:28-45. http://dx.doi.org/10.1152/physiolgenomics.00011.2005.
82. Gupta SL, Carlin JM, Pyati P, Dai W, Pfefferkorn ER, Murphy MJ, Jr. 1994. Antiparasitic and antiproliferative effects of indoleamine 2,3-dioxygenase enzyme expression in human fibroblasts. Infect. Immun. 62:2277-2284.
83. Igietseme JU, Uriri IM, Chow M, Abe E, Rank RG. 1997. Inhibition of intracellular multiplication of human strains of Chlamydia trachomatis by nitric oxide. Biochem. Biophys. Res. Commun. 232:595-601. http://dx.doi.org/10.1006/bbrc.1997.6335.
84. Freidank HM, Billing H, Wiedmann-Al-Ahmad M. 2001. Influence of iron restriction on Chlamydia pneumoniae and C. trachomatis. J. Med. Microbiol. 50:223-227.
85. Pfefferkorn ER. 1984. Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc. Natl. Acad. Sci. U. S. A. 81:908-912. http://dx.doi.org/10.1073/pnas.81.3.908.
86. Murray HW, Szuro-Sudol A, Wellner D, Oca MJ, Granger AM, Libby DM, Rothermel CD, Rubin BY. 1989. Role of tryptophan degradation in respiratory burst-independent antimicrobial activity of gamma interferon-stimulated human macrophages. Infect. Immun. 57:845-849.
87. Adams O, Besken K, Oberdorfer C, MacKenzie CR, Takikawa O, Daubener W. 2004. Role of indoleamine-2,3-dioxygenase in alpha/beta and gamma interferon-mediated antiviral effects against herpes simplex virus infections. J. Virol. 78:2632-2636. http://dx.doi.org/10.1128/JVI.78.5.2632-2636.2004.
88. Byrne GI, Lehmann LK, Kirschbaum JG, Borden EC, Lee CM, Brown RR. 1986. Induction of tryptophan degradation in vitro and in vivo: a gamma-interferon-stimulated activity. J. Interferon Res. 6:389-396. http://dx.doi.org/10.1089/jir.1986.6.389.
89. Byrne GI, Lehmann LK, Landry GJ. 1986. Induction of tryptophan catabolism is the mechanism for gamma-interferon-mediated inhibition of intracellular Chlamydia psittaci replication in T24 cells. Infect. Immun. 53:347-351.
90. Divanovic S, Sawtell NM, Trompette A, Warning JI, Dias A, Cooper AM, Yap GS, Arditi M, Shimada K, Duhadaway JB, Prendergast GC, Basaraba RJ, Mellor AL, Munn DH, Aliberti J, Karp CL. 2012. Opposing biological functions of tryptophan catabolizing enzymes during intracellular infection. J. Infect. Dis. 205:152-161. http://dx.doi.org/10.1093/infdis/jir621.
91. Boasso A. 2011. Wounding the immune system with its own blade: HIV-induced tryptophan catabolism and pathogenesis. Curr. Med. Chem. 18:2247-2256. http://dx.doi.org/10.2174/092986711795656126.
92. Larrea E, Riezu-Boj JI, Gil-Guerrero L, Casares N, Aldabe R, Sarobe P, Civeira MP, Heeney JL, Rollier C, Verstrepen B, Wakita T, Borras-Cuesta F, Lasarte JJ, Prieto J. 2007. Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection. J. Virol. 81:3662-3666. http://dx.doi.org/10.1128/JVI.02248-06.
93. Rollier CS, Paranhos-Baccala G, Verschoor EJ, Verstrepen BE, Drexhage JA, Fagrouch Z, Berland JL, Komurian-Pradel F, Duverger B, Himoudi N, Staib C, Meyr M, Whelan M, Whelan JA, Adams VC, Larrea E, Riezu JI, Lasarte JJ, Bartosch B, Cosset FL, Spaan WJ, Diepolder HM, Pape GR, Sutter G, Inchauspe G, Heeney JL. 2007. Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Hepatology 45:602-613 http://dx.doi.org/10.1002/hep.21573.
94. Mittal D, Kassianos AJ, Tran LS, Bergot AS, Gosmann C, Hofmann J, Blumenthal A, Leggatt GR, Frazer IH. 2013. Indoleamine 2,3-dioxygenase activity contributes to local immune suppression in the skin expressing human papillomavirus oncoprotein e7. J. Invest. Dermatol. 133:2686-2694. http://dx.doi.org/10.1038/jid.2013.222.
95. Popov A, Driesen J, Abdullah Z, Wickenhauser C, Beyer M, Debey-Pascher S, Saric T, Kummer S, Takikawa O, Domann E, Chakraborty T, Kronke M, Utermohlen O, Schultze JL. 2008. Infection of myeloid dendritic cells with Listeria monocytogenes leads to the suppression of T cell function by multiple inhibitory mechanisms. J. Immunol. 181:4976-4988.
96. Desvignes L, Ernst JD. 2009. Interferon-gamma-responsive nonhematopoietic cells regulate the immune response to Mycobacterium tuberculosis. Immunity 31:974-985. http://dx.doi.org/10.1016/j.immuni.2009.10.007.
97. Cheng SC, van de Veerdonk F, Smeekens S, Joosten LA, van der Meer JW, Kullberg BJ, Netea MG. 2010. Candida albicans dampens host defense by downregulating IL-17 production. J. Immunol. 185:2450-2457. http://dx.doi.org/10.4049/jimmunol.1000756.
98. Montagnoli C, Fallarino F, Gaziano R, Bozza S, Bellocchio S, Zelante T, Kurup WP, Pitzurra L, Puccetti P, Romani L. 2006. Immunity and tolerance to Aspergillus involve functionally distinct regulatory T cells and tryptophan catabolism. J. Immunol. 176:1712-1723.
99. Fehlner-Gardiner C, Roshick C, Carlson JH, Hughes S, Belland RJ, Caldwell HD, McClarty G. 2002. Molecular basis defining human Chlamydia trachomatis tissue tropism. A possible role for tryptophan synthase. J. Biol. Chem. 277:26893-26903. http://dx.doi.org/10.1074/jbc. M203937200.
100. Caldwell HD, Wood H, Crane C, Bailey R, Jones RB, Mabey D, Maclean I, Mohammed Z, Peeling R, Roshick C, Schachter J, Solomon AW, Stamm WE, Suchland RJ, Taylor L, West SK, Quinn TC, Belland RJ, McClarty G. 2003. Polymorphisms in Chlamydia trachomatis tryptophan synthase genes differentiate between genital and ocular isolates. J. Clin. Invest. 111:1757-1769. http://dx.doi.org/10.1172/JCI17993.
101. Morrison RP. 2000. Differential sensitivities of Chlamydia trachomatis strains to inhibitory effects of gamma interferon. Infect. Immun. 68: 6038-6040. http://dx.doi.org/10.1128/IAI.68.10.6038-6040.2000.
102. Read TD, Myers GS, Brunham RC, Nelson WC, Paulsen IT, Heidelberg J, Holtzapple E, Khouri H, Federova NB, Carty HA, Umayam LA, Haft DH, Peterson J, Beanan MJ, White O, Salzberg SL, Hsia RC, McClarty G, Rank RG, Bavoil PM, Fraser CM. 2003. Genome sequence of Chlamydophila caviae (Chlamydia psittaci GPIC): examining the role of niche-specific genes in the evolution of the Chlamydiaceae. Nucleic Acids Res. 31:2134-2147. http://dx.doi.org/10.1093/nar/gkg321.
103. Xie G, Bonner CA, Jensen RA. 2002. Dynamic diversity of the tryptophan pathway in chlamydiae: reductive evolution and a novel operon for tryptophan recapture. Genome Biol. 3:research0051. http://dx.doi.org/10.1186/gb-2002-3-9-research0051.
104. Wood H, Roshick C, McClarty G. 2004. Tryptophan recycling is responsible for the interferon-gamma resistance of Chlamydia psittaci GPIC in indoleamine dioxygenase-expressing host cells. Mol. Microbiol. 52:903-916. http://dx.doi.org/10.1111/j.1365-2958.2004.04029.x.
105. Nelson DE, Virok DP, Wood H, Roshick C, Johnson RM, Whitmire WM, Crane DD, Steele-Mortimer O, Kari L, McClarty G, Caldwell HD. 2005. Chlamydial IFN-gamma immune evasion is linked to host infection tropism. Proc. Natl. Acad. Sci. U. S. A. 102:10658-10663. http://dx.doi.org/10.1073/pnas.0504198102.
106. Roulis E, Polkinghorne A, Timms P. 2013. Chlamydia pneumoniae: modern insights into an ancient pathogen. Trends Microbiol. 21:120-128. http://dx.doi.org/10.1016/j.tim.2012.10.009.
107. Read TD, Brunham RC, Shen C, Gill SR, Heidelberg JF, White O, Hickey EK, Peterson J, Utterback T, Berry K, Bass S, Linher K, Weidman J, Khouri H, Craven B, Bowman C, Dodson R, Gwinn M, Nelson W, DeBoy R, Kolonay J, McClarty G, Salzberg SL, Eisen J, Fraser CM. 2000. Genome sequences of Chlamydia trachomatis MoPn and Chlamydia pneumoniae AR39. Nucleic Acids Res. 28:1397-1406. http://dx.doi.org/10.1093/nar/28.6.1397.
108. Shirai M, Hirakawa H, Kimoto M, Tabuchi M, Kishi F, Ouchi K, Shiba T, Ishii K, Hattori M, Kuhara S, Nakazawa T. 2000. Comparison of whole genome sequences of Chlamydia pneumoniae J138 from Japan and CWL029 from USA. Nucleic Acids Res. 28:2311-2314. http://dx.doi.org/10.1093/nar/28.12.2311.
109. Kalman S, Mitchell W, Marathe R, Lammel C, Fan J, Hyman RW, Olinger L, Grimwood J, Davis RW, Stephens RS. 1999. Comparative genomes of Chlamydia pneumoniae and C. trachomatis. Nat. Genet. 21: 385-389. http://dx.doi.org/10.1038/7716.
110. Myers GS, Mathews SA, Eppinger M, Mitchell C, O'Brien KK, White OR, Benahmed F, Brunham RC, Read TD, Ravel J, Bavoil PM, Timms P. 2009. Evidence that human Chlamydia pneumoniae was zoonotically acquired. J. Bacteriol. 191:7225-7233. http://dx.doi.org/10.1128/JB.00746-09.
111. Roulis E, Bachmann N, Polkinghorne A, Hammerschlag M, KohlhoffS, Timms P. 6 February 2014. Draft genome and plasmid sequences of Chlamydia pneumoniae strain B21 from an Australian endangered marsupial, the Western Barred Bandicoot. Genome Announc. http://dx.doi.org/10.1128/genomeA.01223-13.
112. Mitchell CM, Mathews SA, Theodoropoulos C, Timms P. 2009. In vitro characterisation of koala Chlamydia pneumoniae: morphology, inclusion development and doubling time. Vet. Microbiol. 136:91-99. http://dx.doi.org/10.1016/j.vetmic.2008.10.008.
113. Pantoja LG, Miller RD, Ramirez JA, Molestina RE, Summersgill JT. 2001. Characterization of Chlamydia pneumoniae persistence in HEp-2 cells treated with gamma interferon. Infect. Immun. 69:7927-7932. http://dx.doi.org/10.1128/IAI.69.12.7927-7932.2001.
114. Summersgill JT, Sahney NN, Gaydos CA, Quinn TC, Ramirez JA. 1995. Inhibition of Chlamydia pneumoniae growth in HEp-2 cells pretreated with gamma interferon and tumor necrosis factor alpha. Infect. Immun. 63:2801-2803.
115. Mehta SJ, Miller RD, Ramirez JA, Summersgill JT. 1998. Inhibition of Chlamydia pneumoniae replication in HEp-2 cells by interferon-gamma: role of tryptophan catabolism. J. Infect. Dis. 177:1326-1331. http://dx.doi.org/10.1086/515287.
116. Pantoja LG, Miller RD, Ramirez JA, Molestina RE, Summersgill JT. 2000. Inhibition of Chlamydia pneumoniae replication in human aortic smooth muscle cells by gamma interferon-induced indoleamine 2, 3-dioxygenase activity. Infect. Immun. 68:6478-6481. http://dx.doi.org/10.1128/IAI.68.11.6478-6481.2000.
117. Al-Younes HM, Gussmann J, Braun PR, Brinkmann V, Meyer TF. 2006. Naturally occurring amino acids differentially influence the development of Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae. J. Med. Microbiol. 55:879-886. http://dx.doi.org/10.1099/jmm.0.46445-0.
118. Gieffers J, Durling L, Ouellette SP, Rupp J, Maass M, Byrne GI, Caldwell HD, Belland RJ. 2003. Genotypic differences in the Chlamydia pneumoniae tyrP locus related to vascular tropism and pathogenicity. J. Infect. Dis. 188:1085-1093. http://dx.doi.org/10.1086/378692.
119. SchoborgRV. 2011. Chlamydia persistence - a tool to dissect chlamydiahost interactions. Microbes Infect. 13:649-662. http://dx.doi.org/10.1016/j.micinf.2011.03.004.
120. Wyrick PB. 2010. Chlamydia trachomatis persistence in vitro: an overview. J. Infect. Dis. 201(Suppl 2):S88-S95. http://dx.doi.org/10.1086/652394.
121. Lo CC, Xie G, Bonner CA, Jensen RA. 2012. The alternative translational profile that underlies the immune-evasive state of persistence in Chlamydiaceae exploits differential tryptophan contents of the protein repertoire. Microbiol. Mol. Biol. Rev. 76:405-443. http://dx.doi.org/10.1128/MMBR.05013-11.
122. Bonner CA, Byrne GI, Jensen RA. 28 February 2014. Chlamydia exploit the mammalian tryptophan-depletion defense strategy as a counter-defensive cue to trigger a survival state of persistence. Front. Cell. Infect. Microbiol. http://dx.doi.org/10.3389/fcimb.2014.00017.
123. Timms P, Good D, Wan C, Theodoropoulos C, Mukhopadhyay S, Summersgill J, Mathews S. 2009. Differential transcriptional responses between the interferon-gamma-induction and iron-limitation models of persistence for Chlamydia pneumoniae. J. Microbiol. Immunol. Infect. 42:27-37.
124. Schaumburg CS, Tan M. 2006. Arginine-dependent gene regulation via the ArgR repressor is species specific in Chlamydia. J. Bacteriol. 188:919-927. http://dx.doi.org/10.1128/JB.188.3.919-927.2006.
125. Giles TN, Graham DE. 2007. Characterization of an acid-dependent arginine decarboxylase enzyme from Chlamydophila pneumoniae. J. Bacteriol. 189:7376-7383. http://dx.doi.org/10.1128/JB.00772-07.
126. Thomas SR, Terentis AC, Cai H, Takikawa O, Levina A, Lay PA, Freewan M, Stocker R. 2007. Post-translational regulation of human indoleamine 2,3-dioxygenase activity by nitric oxide. J. Biol. Chem. 282: 23778-23787. http://dx.doi.org/10.1074/jbc. M700669200.
127. Giles TN, Fisher DJ, Graham DE. 2009. Independent inactivation of arginine decarboxylase genes by nonsense and missense mutations led to pseudogene formation in Chlamydia trachomatis serovar L2 and D strains. BMC Evol. Biol. 9:166. http://dx.doi.org/10.1186/1471-2148-9-166.
128. Roshick C, Wood H, Caldwell HD, McClarty G. 2006. Comparison of gamma interferon-mediated antichlamydial defense mechanisms in human and mouse cells. Infect. Immun. 74:225-238. http://dx.doi.org/10.1128/IAI.74.1.225-238.2006.
129. Rothfuchs AG, Gigliotti D, Palmblad K, Andersson U, Wigzell H, Rottenberg ME. 2001. IFN-alpha beta-dependent, IFN-gamma secretion by bone marrow-derived macrophages controls an intracellular bacterial infection. J. Immunol. 167:6453-6461.
130. Rottenberg ME, Gigliotti Rothfuchs A, Gigliotti D, Ceausu M, Une C, Levitsky V, Wigzell H. 2000. Regulation and role of IFN-gamma in the innate resistance to infection with Chlamydia pneumoniae. J. Immunol. 164:4812-4818.